ReacciónMódulo 4: Tratamiento. Tratamiento de la tuberculosis farmacorresistente. Actualización del 2022
Módulo 4: Tratamiento. Tratamiento de la tuberculosis farmacorresistente. Actualización del 2022
Índice (versión en línea) :
-
Module 4: treatment and care
- Acknowledgements
- Abbreviations and acronyms
- Definitions
- Executive summary
-
Chapter 1 Drug-susceptible TB treatment
- 1. Introduction
- 2. Key considerations in DS-TB treatment
- 3. Treatment of DS-TB using the 6-month regimen
- 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen
- 5. Treatment of DS-TB using the 4-month 2HRZ(E)/2HR regimen
- 6. Treatment of DS-TB in people living with HIV
- 7. Treatment of extrapulmonary TB
- 8. Treatment of DS-TB in special situations
- 9. Monitoring treatment response
- 10. Outcome definitions
- References (Chapter 1)
-
Chapter 2 Drug-resistant TB treatment
- 1. Introduction
- 2. WHO recommendations on DR-TB treatment
- 3. Key considerations in DR-TB treatment
- 4. Treatment of DR-TB using 6-month regimens
- 5. Treatment of drug-resistant TB using 9-month regimens
- 6. Treatment of drug-resistant TB using longer regimens
- 7. Regimen for rifampicin-susceptible and isoniazid-resistant TB
- 8. Adjuncts to DR-TB treatment and comorbidities
- 9. Programmatic implementation of DR-TB regimens
- References (Chapter 2)
- Chapter 3 Tuberculosis care and support
- Annex 1. Tuberculosis medicine information sheets
- Annex 2. Monitoring and management of adverse events in treatment of drug-resistant tuberculosis
- Annex 3. Active TB drug-safety monitoring and management for treatment of drug-resistant tuberculosis
- Annex 4. Dosing of medicines used in TB regimens, adults and children
VER VERSIÓN PDFCita propuesta: Organización Panamericana de la Salud. Manual operativo de la OMS sobre la tuberculosis. Módulo 4: Tratamiento. Tratamiento de la tuberculosis farmacorresistente. Actualización del 2022. Washington, D.C.: OPS; 2023. Disponible en: https://doi. org/10.37774/9789275327852.